Attovia Therapeutics (NASDAQ:ATTO) Rating Increased to Moderate Buy at Royal Bank Of Canada

Royal Bank Of Canada upgraded shares of Attovia Therapeutics (NASDAQ:ATTO) to a moderate buy rating in a report issued on Sunday,Zacks reports.

A number of other research analysts have also recently issued reports on ATTO. Leerink Partners initiated coverage on shares of Attovia Therapeutics in a research note on Monday. They issued an “outperform” rating and a $52.00 price objective on the stock. Lifesci Capital started coverage on Attovia Therapeutics in a research note on Monday. They set an “outperform” rating and a $45.00 target price for the company. Citigroup initiated coverage on Attovia Therapeutics in a report on Monday. They issued a “buy” rating and a $30.00 target price on the stock. Finally, Morgan Stanley began coverage on Attovia Therapeutics in a report on Monday. They set an “overweight” rating and a $39.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Attovia Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $42.20.

Attovia Therapeutics Stock Up 3.4%

Shares of NASDAQ ATTO opened at $21.40 on Friday. Attovia Therapeutics has a 52 week low of $16.15 and a 52 week high of $24.32.

Insider Transactions at Attovia Therapeutics

In related news, Director Colin Walsh purchased 500,000 shares of the stock in a transaction dated Thursday, August 6th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $8,500,000.00. Following the completion of the acquisition, the director owned 3,020,632 shares of the company’s stock, valued at approximately $51,350,744. This represents a 19.84% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Goldman Sachs Group Inc purchased 500,000 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was purchased at an average price of $17.00 per share, with a total value of $8,500,000.00. Following the completion of the purchase, the insider directly owned 3,020,632 shares in the company, valued at $51,350,744. The trade was a 19.84% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 2,740,587 shares of company stock valued at $47,269,979.

Institutional Investors Weigh In On Attovia Therapeutics

A hedge fund recently raised its position in Attovia Therapeutics stock. BlackRock Inc. increased its position in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 164,358 shares of the company’s stock after acquiring an additional 31,189 shares during the period. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent reporting period.

More Attovia Therapeutics News

Here are the key news stories impacting Attovia Therapeutics this week:

• Positive Sentiment: Broad analyst support: Lifesci Capital initiated coverage with an “outperform” rating and a $45 price target, implying substantial upside from recent trading levels. Benzinga analyst coverage report
• Positive Sentiment: Leerink sets highest target: Leerink Partners began coverage with an “outperform” rating and a $52 target, signaling strong confidence in Attovia’s long-term potential. Benzinga analyst coverage report
• Positive Sentiment: Additional bullish initiations: Citigroup rated the stock “buy” with a $30 target, Royal Bank of Canada rated it “outperform” with a $45 target, and Morgan Stanley initiated an “overweight” rating with a $39 target. The broad agreement among new analysts provides a favorable near-term sentiment catalyst. Benzinga analyst coverage report
• Positive Sentiment: Immunology opportunity highlighted: RBC said Attovia could become a key player in immunology and inflammation, supporting the investment case for the company’s clinical pipeline and market opportunity. Attovia Therapeutics Could Serve as Key Player in Immunology, Inflammation, RBC Says

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.